for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-AstraZeneca Says Brilinta Approved In U.S. In Stroke

Nov 6 (Reuters) - AstraZeneca PLC:

* ASTRAZENECA PLC - BRILINTA APPROVED IN THE US IN STROKE

* ASTRAZENECA - BRILINTA APPROVED IN US TO REDUCE RISK OF STROKE IN PATIENTS WITH AN ACUTE ISCHAEMIC STROKE OR HIGH-RISK TRANSIENT ISCHAEMIC ATTACK

* ASTRAZENECA - NEW INDICATION EXPANDS USE OF BRILINTA BEYOND CARDIOVASCULAR DISEASE TO PATIENTS WITH MILD-TO-MODERATE STROKE

* ASTRAZENECA- APPROVAL BY US FOOD AND DRUG ADMINISTRATION (FDA) WAS BASED ON POSITIVE RESULTS FROM THALES PHASE III TRIAL

* ASTRAZENECA- REGULATORY SUBMISSIONS TO EXPAND APPROVED INDICATION ARE ALSO UNDER REGULATORY REVIEW IN CHINA & EU WHERE MEDICINE’S NAME IS BRILIQUE Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up